Anti-malarial compositions
AssigneesLeidos, Inc., The U.S. of America, as represented by the Secretary, Dept. of Health & Human Services
InventorsGabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
Life of this patent
Estimating the term…
Abstract
This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
Claims14
A method of producing a heavy chain of an antibody, comprising growing a host cell comprising a gene expression construct encoding the heavy chain under conditions which permit expression of the gene expression construct, wherein the gene expression construct comprises a coding sequence for the heavy chain, wherein the variable region of the heavy chain comprises:
- (i) a first heavy chain complementarity determining region (CDRH) comprising the amino acid sequence SEQ ID NO:1;
- a second CDRH comprising the amino acid sequence SEQ ID NO:2;
- and a third CDRH comprising the amino acid sequence SEQ ID NO:3;
- or
- (ii) the complementarity determining regions of the heavy chain variable region of the antibody deposited under Accession No. MRA-1242.
A method of producing a light chain of an antibody, comprising growing a host cell comprising a gene expression construct encoding the light chain under conditions which permit expression of the gene expression construct, wherein the gene expression construct comprises a coding sequence for the light chain, wherein the variable region of the light chain comprises:
- (i) a first CDRL comprising the amino acid sequence SEQ ID NO:4;
- a second CDRL comprising the amino acid sequence SEQ ID NO:5;
- and a third CDRL comprising the amino acid sequence SEQ ID NO:6;
- or
- (ii) the CDRs of the light chain variable region of the antibody deposited under Accession No. MRA-1242.
Dependencies are inferred from the claim text.